First-line therapy for advanced non-small cell lung cancer with activating EGFR mutation: is combined EGFR-TKIs and chemotherapy a better choice?
S Wang, A Gao, J Liu, Y Sun - Cancer chemotherapy and pharmacology, 2018 - Springer
As the standard first-line treatment for advanced non-small cell lung cancer (NSCLC) with
activating epidermal growth factor receptor (EGFR) mutation, EGFR-tyrosine kinase …
activating epidermal growth factor receptor (EGFR) mutation, EGFR-tyrosine kinase …
Alternating therapy with osimertinib and afatinib for treatment-naive patients with EGFR-mutated advanced non-small cell lung cancer: a single-group, open-label …
H Hayashi, K Yonesaka, A Nakamura, D Fujimoto… - Lung Cancer, 2022 - Elsevier
Introduction Alternation of osimertinib and afatinib is a potential approach to overcome
osimertinib resistance and to allow complementation of drug efficacy without compromising …
osimertinib resistance and to allow complementation of drug efficacy without compromising …
EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer
K Otsuka, A Hata, J Takeshita, C Okuda, R Kaji… - Cancer chemotherapy …, 2015 - Springer
Background Efficacies of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor
(TKI) rechallenge have been demonstrated in EGFR-mutant non-small cell lung cancer …
(TKI) rechallenge have been demonstrated in EGFR-mutant non-small cell lung cancer …
Dual Inhibition of EGFR with Afatinib and Cetuximab in Kinase Inhibitor–Resistant EGFR-Mutant Lung Cancer with and without T790M Mutations
EGFR-mutant lung cancers responsive to reversible EGFR inhibitors (gefitinib/erlotinib)
develop acquired resistance, mediated by second-site EGFR T790M mutation in> 50% of …
develop acquired resistance, mediated by second-site EGFR T790M mutation in> 50% of …
[HTML][HTML] A retrospective study of low-dose apatinib combined with S-1 in patients with advanced non-small cell lung cancer
T Zhou, C Wu, C Zhang, P Li, H Dong… - Journal of Thoracic …, 2019 - ncbi.nlm.nih.gov
Background The current regimens for advanced non-small cell lung cancer (NSCLC)
patients are deficient due to failings in standard treatments. This retrospective study aimed to …
patients are deficient due to failings in standard treatments. This retrospective study aimed to …
Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: an observational study
MJ Hochmair, A Morabito, D Hao, CT Yang… - Future …, 2018 - Future Medicine
Aim: To assess outcomes in patients with EGFR mutation-positive (Del19, L858R) non-small-
cell lung cancer receiving sequential afatinib and osimertinib in a real-world clinical setting …
cell lung cancer receiving sequential afatinib and osimertinib in a real-world clinical setting …
Phase 2 Study of Afatinib Alone or Combined With Bevacizumab in Chemonaive Patients With Advanced Non–Small-Cell Lung Cancer Harboring EGFR Mutations …
T Ninomiya, N Ishikawa, K Inoue, T Kubo, M Yasugi… - Clinical Lung Cancer, 2019 - Elsevier
Afatinib, a second-generation epidermal growth factor receptor (EGFR)-tyrosine kinase
inhibitor (TKI), has demonstrated a significant survival benefit over platinum-based …
inhibitor (TKI), has demonstrated a significant survival benefit over platinum-based …
[HTML][HTML] Multi-targeted tyrosine kinase inhibitors as third-line regimen in advanced non-small cell lung cancer: a network meta-analysis
Z Zhang, Y Zhao, F Lu, X Hou, Y Ma, F Luo… - Annals of …, 2019 - ncbi.nlm.nih.gov
Background Four multi-targeted tyrosine kinase inhibitors (TKIs) including apatinib,
anlotinib, fruquintinib and lenvatinib are currently available as third-line regimen for …
anlotinib, fruquintinib and lenvatinib are currently available as third-line regimen for …
A Phase II Study of Osimertinib Combined With Platinum Plus Pemetrexed in Patients With EGFR-Mutated Advanced Non–Small-cell Lung Cancer: The OPAL Study …
H Asahina, K Tanaka, S Morita, M Maemondo… - Clinical Lung Cancer, 2021 - Elsevier
Background Osimertinib, a third-generation epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor, is now a standard treatment of previously untreated EGFR-mutated …
tyrosine kinase inhibitor, is now a standard treatment of previously untreated EGFR-mutated …
A phase II, multicenter, placebo-controlled trial of apatinib in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) after two previous treatment …
L Zhang, M Shi, C Huang, X Liu, J Xiong, G Chen… - 2012 - ascopubs.org
7548 Background: Apatinib is an oral, small molecular tyrosine-kinase inhibitor (TKI)
targeting vascular endothelial growth factor receptor (VEGFR). Phase II study has showed …
targeting vascular endothelial growth factor receptor (VEGFR). Phase II study has showed …